Carboplatin

In oncology, carboplatin is an "organoplatinum compound that possesses antineoplastic activity."

History
In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989. A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.